Catenion co-founder and senior partner Markus Thunecke presents the main findings of Catenion’s R&D productivity longitudinal study. Catenion began systematically analyzing the R&D productivity of pharma companies about ten years ago because good analysis was not available: most companies only tracked approvals of new molecular entities, and everyone claimed to beat the average, which is mathematically impossible.
Methodology: R&D productivity has R&D spending, adjusted for the cost of M&A, as the denominator, and the present value of the pipeline plus the value of products launched in the last eight years (long-term ratio), or the NPV of the pipeline alone (short-term ratio), as the numerator. Corporate growth is tracked through sales, EBITDA and market cap for the 30 largest public biopharma companies.
Performance clusters:
- Novo Nordisk, the lone winner: always in the top five thanks to a relentless focus on metabolic disease and GLP-1 medicines, and driven for many years by internal research rather than deals.
- Turnaround champions AstraZeneca and Lilly: both started as typical big pharma underperformers facing patent cliffs. AstraZeneca shows the power of portfolio decision-making (its 5R framework) combined with focused internal and external innovation. Lilly changed its approach to R&D to bring more accountability and nimbleness by mimicking biotech-like structures and governance.
- Companies that benefited from recent and not always sustainable upsurges: Pfizer (COVID), Daiichi Sankyo (antibody-drug conjugates and deals) and Eisai (Alzheimer’s antibodies).
- Biogen and Gilead, which failed to scale up their once-strong R&D and corporate growth outperformance.
Key drivers of R&D productivity: - Size: above a critical mass of roughly a 1 to 2 billion R&D budget, size becomes a burden, and mid-sized companies are over-represented in the top 10.
- Focus: doubling down on complex scientific areas beats spreading resources thinly.
- Therapeutic area mix: oncology has an intrinsic advantage (spin-off indications after proof of concept), while CNS and cardiovascular correlate negatively with productivity.
- Key high-value assets: the best thing for R&D productivity is a pipeline in a product, provided it is recognized early and developed broadly.
- Internal versus external innovation: contrary to the “search and develop” narrative, internal R&D is behind the performance of many top-10 companies, and the best performers run hybrid models in which strong internal capabilities let them pick external winners early.
Conclusion: outperformance over long periods is possible, even for big pharma coming back from underperformance. The biggest challenge is to sustain it without falling into bureaucracy and poor ownership, and investing in the quality of decision-making is probably the quickest way to improve R&D productivity.



